LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Alector to Participate in Upcoming Healthcare Conferences

August 28, 2025 | Last Trade: US$2.80 0.05 1.64

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

  • Cantor Global Healthcare Conference 2025 (New York, New York)
    • Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat
  • Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York)
    • Monday, September 8, 2025, at 10:00 a.m. ET, fireside chat
  • H.C. Wainwright 27th Annual Global Investment Conference (New York, New York)
    • Tuesday, September 9, 2025, at 1:30 p.m. ET, company presentation

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
This email address is being protected from spambots. You need JavaScript enabled to view it.

Argot Partners (media)
David Rosen
646-461-6387
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Argot Partners (investors)
Laura Perry
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page